Between January 1990 and December 1997, 182 adults with @entity981 ( @entity981 ) received allogeneic hematopoietic cell transplants according to Fred @entity5 Research Center protocols. @entity1 eligible for transplantation included those in first remission, especially those at high risk of relapse (n = 41), and any @entity1 in second or later remissions (n = 46) or in relapse (n = 95). The median @entity1 age was 29.4 years (range, 18.0-57.6 years), and the median duration of disease was 13.3 months (range, 2.4-221.9 months). Fifty-six @entity1 had @entity981 . Most @entity1 (n = 169) received a conditioning regimen of @entity786 120 mg/kg plus 12.0 to 15.75 Gy of total body irradiation and a combination of @entity205 and @entity1499 as @entity2132 ( @entity2132 ) prophylaxis. One hundred twenty-one @entity1 received stem cells from HLA-identical donors (88 related donors and 33 unrelated donors), and 61 received stem cells from HLA-mismatched donors (26 related donors and 35 unrelated donors). Actuarial disease-free survival at 5 years was 21% for all @entity1 , 43% for @entity1 in first remission, 24% for @entity1 in second or later remissions, and 9% for @entity1 in relapse. Univariate and multivariate Cox regression analyses were performed to identify factors associated with survival, relapse, nonrelapse mortality, and disease-free survival. Factors significantly associated (P <.01) with improved survival and disease-free survival included younger age and being in first remission. Lower disease-free survival was associated with receiving @entity205 alone as @entity2132 prophylaxis (P <.01). Risk of relapse correlated only with disease status at transplantation: @entity1 who underwent transplantation in relapse had a 9-fold increased risk compared with @entity1 who underwent transplantation in first remission. Acute or chronic @entity2132 had no significant effect on relapse. Increased nonrelapse mortality was associated with HLA-mismatched donors, a positive @entity2803 serology before transplantation, and @entity2132 prophylaxis with only @entity205 . @entity1 with @entity981 had survival and relapse rates similar to @entity1 with normal cytogenetics.

Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity2803 :: ('MESH:D003586', 'Disease') :: ['cytomegalovirus'] @entity981 :: ('MESH:D054198', 'Disease') :: ['Philadelphia chromosome-positive ALL', 'ALL', 'acute lymphoblastic leukemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Hutchinson Cancer'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-versus-host disease'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukemia']
